Chantal Tasset

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Séverine Vermeire, Stefan Schreiber, Robert Petryka et al. · The Lancet · 2016 · 432 citations

Fitzroy Study, Gastroenterology, Clinical Gastroenterology +4

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan, Silvio Danese, Edward V. Loftus et al. · The Lancet · 2021 · 415 citations

Inflammation, Chronic Inflammatory Diseases, Functional Gastrointestinal Disorder +5

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg et al. · JAMA · 2019 · 305 citations · Full text

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet · 2018 · 251 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +7

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

Bernard Combe, Alan Kivitz, Yoshiya Tanaka et al. · Annals of the Rheumatic Diseases · 2021 · 228 citations · Full text